Our published clinical study
Slash
Double blinded clinical study
The SLASH study was conducted on 40 patients undergoing breast reduction surgery. Each patient had only 1 horizontal breast scar treated with UrgoTouch, the other horizontal scar of the other breast remained untreated. Patients and examinators were unaware of which scar had been treated with the laser. Therefore, each patient was its own control, which, given that the biological scarring process varies greatly from a patient to another, was essential to reduce all biaises.
Non-biased scar analysis
How the scars were analyzed:
- 3D Photo software:
The scars showed significant volume, surface and roughness improvement when treated with the laser. - Clinical examination by the investigators:
The evaluators who analysed the scars (after 14 days, 6 weeks, 3 months, 6 months and 1 year) were different from the surgeons who had performed the surgery on the participants and were thus unaware of which one of the two patients’ scars had been treated with UrgoTouch. - Patients:
The patients who participated to the study were not aware of the which one of their two scars have been treated with UrgoTouch.
The results
UrgoTouch® optimizes the scar by reducing the randomness in the healing process associated with this molecular pathway.
-53%
Up to 53% less scar volume**
-17%
On average minus 17% skin roughness*
100%
100% of the doctors preferred the treated scars vs control*
Twice as many patients preferring their laser-treated scar as the number of patients preferring their control scar (p = 0.024)*.
Results without UrgoTouch®
Scar with fibrosis
Results with UrgoTouch®
Softer and less voluminous scar
PATIENT 8
PATIENT 48
PATIENT 29
PATIENT 5
*A 1 Year Follow-up of Post-operative Scars After the Use of a 1210nm Laser Assisted Skin Healing (LASH) Technology: A Randomized Controlled Trial. D.Casanova, ed. Aesthetic Plastic Surgery Journal. Feb 2017 – **53% reduction observed in a patient with dark skin – Half of the 80 scars were treated with UrgoTouch®